Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cook Medical expands vascular closure device alliance with Cardica:

This article was originally published in Clinica

Executive Summary

Cardica is to develop an additional vascular closure product for Cook Medical, following the expansion of an existing product development agreement. Cook will pay Redwood City, California-based Cardica up to $750,000 for the product design and pre-clinical development of the product, which will incorporate the latter's proprietary microclip technology. Cardica will also benefit from royalties on future sales of the product. Cook, of Bloomington, Indiana, will be responsible for clinical development and regulatory approval, and have exclusive commercialisation rights. The two companies became partners in June to collaborate on a device for treating patent foramen ovale (PFO), a congenital defect commonly known as "hole in the heart" (see Clinica No 1262, p 13).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel